Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.11 | N/A | +111.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.11 | N/A | +111.28% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Management highlighted the strong earnings performance, particularly in EPS. They emphasized their commitment to ongoing strategic initiatives without offering specific revenue guidance.
Management expressed satisfaction with the strong EPS performance.
The company remains focused on its strategic initiatives.
No specific revenue guidance was provided, but the outlook remains positive.
United Therapeutics reported a strong EPS performance, significantly exceeding expectations. The stock reacted positively, rising 1.73% after the announcement. However, the lack of revenue data and guidance may leave investors cautious about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Jul 22, 2013